? The Vanderbilt University School of Medicine is applying for partial support for the acquisition of a small animal PET scanner for studying rodents and primates. This scanner will significantly enhance and extend currently funded NIH research at Vanderbilt in the areas of cancer research and neuroscience research. At present, nine NIH funded investigators have projects requiring a small animal PET scanner for studies of tumor growth, gene expression, malignant transformation, metastatic spread, cerebral plasticity, forebrain development, antipsychotic drug, mechanisms of action, cerebral neurotransmitter interactions, and hallucinogenic drugs. Although Vanderbilt has a well equipped PET Center for clinical diagnosis and clinical research the GE Advance scanner is saturated by clinical and clinical research use, and a reconstructed resolution of a tissue of 5-6mm, which is inadequate for rodent studies and suboptimal for primate brain studies. PET radiopharmaceuticals needed for this research are available from the Vanderbilt PET Radiochemistry Laboratory. The small animal PET scanner will be operated by a user facility under the direction of Dr. Robert Kessler with the oversight of an Advisory Committee who will assure equal access to all NIH funded investigators. The facility will be staffed by physics and processing staff as well as Dr. Kessler who will aid new users in experimental design, data acquisition and analysis. The small animal PET scanner is a critical component in the long-term research plan at the Vanderbilt University School of Medicine. It will be sited physically within the PET Center administratively within the newly formed Center for Research Imaging under the Direction of Dr. John Gore. ? ?

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Biomedical Research Support Shared Instrumentation Grants (S10)
Project #
1S10RR017858-01
Application #
6581711
Study Section
Special Emphasis Panel (ZRG1-SRB (05))
Program Officer
Tingle, Marjorie
Project Start
2003-06-01
Project End
2004-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
1
Fiscal Year
2003
Total Cost
$500,000
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Tantawy, Mohammed N; Charles Manning, H; Peterson, Todd E et al. (2018) Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model. Mol Imaging Biol 20:200-204
Tang, Dewei; Li, Jun; Buck, Jason R et al. (2017) Evaluation of TSPO PET Ligands [18F]VUIIS1009A and [18F]VUIIS1009B: Tracers for Cancer Imaging. Mol Imaging Biol 19:578-588
Whisenant, Jennifer G; McIntyre, J Oliver; Peterson, Todd E et al. (2015) Utility of [18?F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts. Mol Imaging Biol 17:119-28
Cheung, Yiu-Yin; Nickels, Michael L; Tang, Dewei et al. (2014) Facile synthesis of SSR180575 and discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, a potent pyridazinoindole ligand for PET imaging of TSPO in cancer. Bioorg Med Chem Lett 24:4466-4471
Hight, Matthew R; Cheung, Yiu-Yin; Nickels, Michael L et al. (2014) A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Clin Cancer Res 20:2126-35
Whisenant, Jennifer G; Sorace, Anna G; McIntyre, J Oliver et al. (2014) Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts. Transl Oncol 7:768-79
Whisenant, Jennifer G; Ayers, Gregory D; Loveless, Mary E et al. (2014) Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer. Magn Reson Imaging 32:245-9
Tang, Dewei; Nickels, Michael L; Tantawy, M Noor et al. (2014) Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5,7-Diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([ (18)F]VUIIS1008) in glioma. Mol Imaging Biol 16:813-20
Tang, Dewei; McKinley, Eliot T; Hight, Matthew R et al. (2013) Synthesis and structure-activity relationships of 5,6,7-substituted pyrazolopyrimidines: discovery of a novel TSPO PET ligand for cancer imaging. J Med Chem 56:3429-33
McKinley, Eliot T; Ayers, Gregory D; Smith, R Adam et al. (2013) Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One 8:e58938

Showing the most recent 10 out of 16 publications